# Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC

> **NCT04691947** · PHASE1 · COMPLETED · sponsor: **Health Institutes of Turkey** · enrollment: 44 (actual)

## Conditions studied

- COVID-19 Vaccine

## Interventions

- **BIOLOGICAL:** ERUCOV-VAC
- **OTHER:** Placebo Vaccine

## Key facts

- **NCT ID:** NCT04691947
- **Lead sponsor:** Health Institutes of Turkey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-11-05
- **Primary completion:** 2021-11-18
- **Final completion:** 2021-11-18
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-02-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04691947

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04691947, "Safety and Immunogenicity of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04691947. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*